Pharmaceutical manufacturers of Chloroquine phosphate

Sanofi is a global healthcare leader committed to improving lives around the world. With a strong focus on research and development, Sanofi strives to transform scientific innovation into healthcare solutions that address unmet medical needs. The company's extensive portfolio spans prescription medicines, vaccines, consumer healthcare products, and biopharmaceuticals, covering a wide range of therapeutic areas, including diabetes, cardiovascular disease, oncology, immunology, rare diseases, and vaccines.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 employees, Natco today has eight manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc. Natco family currently consists of around 4500 employees, we are consistently ranked among fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in Pharmaceutical R&D.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Suven Pharmaceuticals Limited, an organization established in November 2018, has transformed into a Wholly Owned Subsidiary of Suven Life Sciences Limited, effective from February 2019. Suven Life Sciences Limited, following the Board meeting on February 5, 2019, declared the demerger of Suven Life Sciences Limited into two parts: Suven Life Sciences Limited, the demerged entity, will persist in pioneering research dedicated to Central Nervous System (CNS) disorders to address significant unmet medical needs worldwide. Suven Pharmaceuticals Limited, the resulting entity, will carry on the CRAMS business operations.